Review decision – July 2018
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA329: Infliximab, adalimumab and golimumab for the second line treatment of moderately to severely active ulcerative colitis.
Since the original guidance, there has been no direct evidence from head-to-head trials of adalimumab, infliximab and golimumab. As such, there is no new clinical evidence that would change the recommendations of TA329. The companies have confirmed that no changes are anticipated in marketing authorisations or costs. However, the price of infliximab varies depending on whether the reference version of infliximab or biosimilar versions are used. The availability of infliximab and adalimumab biosimilars will not change the recommendations; the recommendations specify that if more than 1 treatment is suitable, the least expensive should be chosen.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently, TA329 will move to the ‘static list’ of technology appraisals.
This page was last updated: